Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2010 1
2011 1
2012 3
2013 5
2015 1
2017 2
2018 2
2019 2
2020 1
2022 3
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Results by year

Filters applied: . Clear all
Page 1
EZH2 targeting induces CD38 upregulation and response to anti-CD38 immunotherapies in multiple myeloma.
Chemlal D, Varlet E, Machura A, Ovejero S, Requirand G, Robert N, Cartron G, Alaterre E, Bret C, Vincent L, Herbaux C, Cavalli G, Bruyer A, De Boussac H, Moreaux J. Chemlal D, et al. Among authors: de boussac h. Leukemia. 2023 Sep;37(9):1925-1928. doi: 10.1038/s41375-023-01983-0. Epub 2023 Aug 2. Leukemia. 2023. PMID: 37532787 Free PMC article. No abstract available.
Oxysterol receptors and their therapeutic applications in cancer conditions.
De Boussac H, Alioui A, Viennois E, Dufour J, Trousson A, Vega A, Guy L, Volle DH, Lobaccaro JM, Baron S. De Boussac H, et al. Expert Opin Ther Targets. 2013 Sep;17(9):1029-38. doi: 10.1517/14728222.2013.820708. Epub 2013 Jul 22. Expert Opin Ther Targets. 2013. PMID: 23875732 Review.
Oxysterol receptors, AKT and prostate cancer.
Dufour J, Viennois E, De Boussac H, Baron S, Lobaccaro JM. Dufour J, et al. Among authors: de boussac h. Curr Opin Pharmacol. 2012 Dec;12(6):724-8. doi: 10.1016/j.coph.2012.06.012. Epub 2012 Jul 19. Curr Opin Pharmacol. 2012. PMID: 22819197 Review.
ABCC6 as a target in pseudoxanthoma elasticum.
Váradi A, Szabó Z, Pomozi V, de Boussac H, Fülöp K, Arányi T. Váradi A, et al. Among authors: de boussac h. Curr Drug Targets. 2011 May;12(5):671-82. doi: 10.2174/138945011795378612. Curr Drug Targets. 2011. PMID: 21039331 Free PMC article. Review.
Comprehensive characterization of the epigenetic landscape in Multiple Myeloma.
Alaterre E, Ovejero S, Herviou L, de Boussac H, Papadopoulos G, Kulis M, Boireau S, Robert N, Requirand G, Bruyer A, Cartron G, Vincent L, Martinez AM, Martin-Subero JI, Cavalli G, Moreaux J. Alaterre E, et al. Among authors: de boussac h. Theranostics. 2022 Jan 16;12(4):1715-1729. doi: 10.7150/thno.54453. eCollection 2022. Theranostics. 2022. PMID: 35198065 Free PMC article.
Enolase is regulated by Liver X Receptors.
De Boussac H, Maqdasy S, Trousson A, Zelcer N, Volle DH, Lobaccaro JM, Baron S. De Boussac H, et al. Steroids. 2015 Jul;99(Pt B):266-71. doi: 10.1016/j.steroids.2015.02.010. Epub 2015 Feb 21. Steroids. 2015. PMID: 25708389
Combined inhibition of Wee1 and Chk1 as a therapeutic strategy in multiple myeloma.
Bruyer A, Dutrieux L, de Boussac H, Martin T, Chemlal D, Robert N, Requirand G, Cartron G, Vincent L, Herbaux C, Lutzmann M, Bret C, Pasero P, Moreaux J, Ovejero S. Bruyer A, et al. Among authors: de boussac h. Front Oncol. 2023 Dec 6;13:1271847. doi: 10.3389/fonc.2023.1271847. eCollection 2023. Front Oncol. 2023. PMID: 38125947 Free PMC article.
The BLM helicase is a new therapeutic target in multiple myeloma involved in replication stress survival and drug resistance.
Ovejero S, Viziteu E, Dutrieux L, Devin J, Lin YL, Alaterre E, Jourdan M, Basbous J, Requirand G, Robert N, de Boussac H, Seckinger A, Hose D, Vincent L, Herbaux C, Constantinou A, Pasero P, Moreaux J. Ovejero S, et al. Among authors: de boussac h. Front Immunol. 2022 Dec 9;13:983181. doi: 10.3389/fimmu.2022.983181. eCollection 2022. Front Immunol. 2022. PMID: 36569948 Free PMC article.
Kinome expression profiling to target new therapeutic avenues in multiple myeloma.
de Boussac H, Bruyer A, Jourdan M, Maes A, Robert N, Gourzones C, Vincent L, Seckinger A, Cartron G, Hose D, De Bruyne E, Kassambara A, Pasero P, Moreaux J. de Boussac H, et al. Haematologica. 2020 Mar;105(3):784-795. doi: 10.3324/haematol.2018.208306. Epub 2019 Jul 9. Haematologica. 2020. PMID: 31289205 Free PMC article.
Inhibition of the Protein Arginine Methyltransferase PRMT5 in High-Risk Multiple Myeloma as a Novel Treatment Approach.
Vlummens P, Verhulst S, De Veirman K, Maes A, Menu E, Moreaux J, De Boussac H, Robert N, De Bruyne E, Hose D, Offner F, Vanderkerken K, Maes K. Vlummens P, et al. Among authors: de boussac h. Front Cell Dev Biol. 2022 Jun 8;10:879057. doi: 10.3389/fcell.2022.879057. eCollection 2022. Front Cell Dev Biol. 2022. PMID: 35757005 Free PMC article.
21 results